Malaria Vaccine Parasite Replication Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current malaria vaccines targeting the blood-stage have faced challenges in scalability and efficacy, with subunit vaccines struggling to induce effective immune responses due to the need for large parasite doses and adjuvant compatibility issues, while whole parasite approaches are logistically and safely unfeasible.

Innovation Solution

Co-administration of blood-stage malaria parasites or infected red blood cells with a delayed death agent, such as doxycycline, allows limited parasite replication and immune system exposure without the need for adjuvants, inducing a cellular immune response and preventing severe infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If whole blood-stage parasites are administered to induce cellular immune response, then vaccine efficacy is improved, but the required parasite dose becomes unfeasibly large for scalable production

Engineering Contradiction:

Improvevaccine efficacyVSAvoidparasite dose required

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by administering a delayed death agent (doxycycline) before and during parasite administration. This pre-treatment with the delayed death agent controls parasite replication in advance, allowing the use of much lower parasite doses (10-1000 times lower than previously required) while still inducing effective cellular immune responses. The delayed death agent ensures parasites remain controlled during the critical immune response induction period.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The delayed death agent (doxycycline) serves as an intermediary substance that mediates between the vaccine developer and the parasite. It allows controlled interaction with the parasites during vaccination, enabling immune response induction while preventing uncontrolled parasite proliferation. This intermediary approach solves the scalability problem by making parasite dose requirements feasible for mass production.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If high doses of parasites are used to ensure sufficient immune stimulation, then immune response is improved, but safety concerns increase due to risk of severe infection

Engineering Contradiction:

Improveimmune response strengthVSAvoidrisk of severe infection

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The delayed death agent is administered in advance and continued during parasite exposure to pre-establish control over parasite replication. This preliminary control measures safety concerns before they can materialize, allowing sufficient immune stimulation without the risk of severe infection that would occur with high-dose unprotected parasite administration.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the potentially harmful effect of parasite replication into a beneficial controlled process. The delayed death agent allows limited, controlled parasite replication that is sufficient to induce immune responses while preventing the uncontrolled replication that would cause severe disease. The harmful replication potential is thus transformed into a controlled, beneficial immune-stimulating process.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Ease of manufacture

If subunit vaccines are used to avoid scalability issues, then manufacturing feasibility is improved, but vaccine efficacy decreases due to inability to induce strong cellular immune response

Engineering Contradiction:

Improvevaccine scalabilityVSAvoidcellular immune response

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

By pre-treating with the delayed death agent, the patent enables the use of whole parasites at low doses without scalability issues. The preliminary control measure allows whole parasite vaccination (which induces strong cellular immunity) to be performed safely and scalably, combining the manufacturing feasibility of subunit vaccines with the immunogenicity of whole parasite vaccines.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively immunizes against malaria by allowing the immune system to mount a protective response while preventing serious infection, potentially applicable to other apicomplexan parasites like Babesia, and eliminates the requirement for adjuvants, enhancing vaccine scalability and safety.

Implementation Method 1

The delayed death agent inhibits protein synthesis in the apicoplast, a plastid-like organelle in apicomplexan parasites

Methodology Applied

Scientific EffectProtein synthesis inhibition:

Data Source

PatentUS11406694B2Vaccine comprising drug and parasite administration

Publication Date: 2022.08.09 GRIFFITH UNIVERSITY

AI summary

Apicomplexan parasites or red blood cells infected with apicomplexan parasites are administered to an animal in combination with a delayed death agent that initially allows parasite replication but subsequently kills the apicomplexan parasites. This allows the elicitation of an immune response by the animal while preventing the parasites producing a serious infection of the animal. The apicomplexan parasites may be malaria or babesia parasites. The delayed death agent may be a tetracycline class antibiotic, a macrolide antibiotic or a lincosamide antibiotic.